Population Health Research Institute, McMaster University, Hamilton, ON, Canada.
N Engl J Med. 2012 Jan 12;366(2):120-9. doi: 10.1056/NEJMoa1105575.
One quarter of strokes are of unknown cause, and subclinical atrial fibrillation may be a common etiologic factor. Pacemakers can detect subclinical episodes of rapid atrial rate, which correlate with electrocardiographically documented atrial fibrillation. We evaluated whether subclinical episodes of rapid atrial rate detected by implanted devices were associated with an increased risk of ischemic stroke in patients who did not have other evidence of atrial fibrillation.
We enrolled 2580 patients, 65 years of age or older, with hypertension and no history of atrial fibrillation, in whom a pacemaker or defibrillator had recently been implanted. We monitored the patients for 3 months to detect subclinical atrial tachyarrhythmias (episodes of atrial rate >190 beats per minute for more than 6 minutes) and followed them for a mean of 2.5 years for the primary outcome of ischemic stroke or systemic embolism. Patients with pacemakers were randomly assigned to receive or not to receive continuous atrial overdrive pacing.
By 3 months, subclinical atrial tachyarrhythmias detected by implanted devices had occurred in 261 patients (10.1%). Subclinical atrial tachyarrhythmias were associated with an increased risk of clinical atrial fibrillation (hazard ratio, 5.56; 95% confidence interval [CI], 3.78 to 8.17; P<0.001) and of ischemic stroke or systemic embolism (hazard ratio, 2.49; 95% CI, 1.28 to 4.85; P=0.007). Of 51 patients who had a primary outcome event, 11 had had subclinical atrial tachyarrhythmias detected by 3 months, and none had had clinical atrial fibrillation by 3 months. The population attributable risk of stroke or systemic embolism associated with subclinical atrial tachyarrhythmias was 13%. Subclinical atrial tachyarrhythmias remained predictive of the primary outcome after adjustment for predictors of stroke (hazard ratio, 2.50; 95% CI, 1.28 to 4.89; P=0.008). Continuous atrial overdrive pacing did not prevent atrial fibrillation.
Subclinical atrial tachyarrhythmias, without clinical atrial fibrillation, occurred frequently in patients with pacemakers and were associated with a significantly increased risk of ischemic stroke or systemic embolism. (Funded by St. Jude Medical; ASSERT ClinicalTrials.gov number, NCT00256152.).
四分之一的中风病因不明,而亚临床心房颤动可能是一个常见的病因。起搏器可以检测到快速心房率的亚临床发作,这与心电图记录的心房颤动相关。我们评估了在没有其他证据表明存在心房颤动的情况下,通过植入设备检测到的快速心房率的亚临床发作是否与缺血性中风风险增加有关。
我们招募了 2580 名年龄在 65 岁或以上、患有高血压且没有心房颤动病史的患者,他们最近植入了起搏器或除颤器。我们监测了这些患者 3 个月,以检测亚临床性房性心动过速(心房率>190 次/分钟持续超过 6 分钟的发作),并在平均 2.5 年的时间里对主要结局缺血性中风或全身性栓塞进行随访。接受起搏器植入的患者被随机分配接受或不接受连续心房超速起搏。
到 3 个月时,通过植入设备检测到的亚临床性房性心动过速发生在 261 名患者(10.1%)中。亚临床性房性心动过速与临床心房颤动的风险增加相关(风险比,5.56;95%置信区间[CI],3.78 至 8.17;P<0.001),也与缺血性中风或全身性栓塞的风险增加相关(风险比,2.49;95%CI,1.28 至 4.85;P=0.007)。在 51 名发生主要结局事件的患者中,有 11 名在 3 个月时检测到亚临床性房性心动过速,且均在 3 个月时未发生临床心房颤动。与亚临床性房性心动过速相关的中风或全身性栓塞人群归因风险为 13%。亚临床性房性心动过速在调整了中风预测因素后仍然是主要结局的预测因素(风险比,2.50;95%CI,1.28 至 4.89;P=0.008)。连续心房超速起搏并不能预防心房颤动。
在植入起搏器的患者中,亚临床性房性心动过速(无临床心房颤动)频繁发生,且与缺血性中风或全身性栓塞的风险显著增加相关。(由圣犹达医疗公司资助;ASSERT 临床试验.gov 编号,NCT00256152。)